Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: prostate adenocarcinoma | prostate cancer | castration-resistant prostate carcinoma | metastatic prostate carcinoma
Age: Between 18 - 100 Years
In order to be eligible to take part in this trial, patients must meet the following criteria:
- Histologically confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate)
- Previous chemotherapy with at least 3 cycles of docetaxel for hormone-sensitive metastatic prostate cancer
For a full list of participation criteria, please visit clinicaltrials.gov.
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required